Stock Award Plans and Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:

	For the Three Months Ended					For the Six Months Ended
	June 30,					June 30,
	2024			2023		2024		2023
Cost of goods sold	$	(10,591	)	$	22,114	$	12,796	$	42,593
Research and development		8,719			34,308		32,964		(35,419	)
Selling, clinical and marketing		7,190			49,592		53,251		91,448
Selling, general and administrative		(97,211	)		174,047		129,384		352,466
Total	$	(91,893	)	$	280,061	$	228,395	$	451,088